跳至主要内容
临床试验/JPRN-UMIN000036099
JPRN-UMIN000036099已完成未知

Safety and efficacy of glecaprevir/pibrentasvir combination therapy for hemodialysis patients with genotype 2 hepatitis C infection - G/P for HD patients with GT2 HCV

Hokkaido University Hospital0 个研究点目标入组 40 人开始时间: 2019年3月6日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1 Patients with a past history of hypersensitivity to HCV protease inhibitors and NS5A inhibitors 2 Patients with serious liver dysfunction (Child-Pugh Class B or C) 3 Patients with difficult-to-control heart disease (e.g., myocardial infarction, heart failure, and arrhythmia) 4 Patients who have malignant tumors, including hepatoma, at the start of treatment 5 Patients on treatment with drugs listed in the contraindications for coadministration in the package insert (e.g., some antifungals, some antiepileptics, and human immunodeficiency virus (HIV) protease inhibitors) 6 Other patients judged to be inappropriate to participate in the study by the primary physician

研究者

相似试验